Go Pro
→ Elon gets it. Do you? (From Porter & Company) (Ad)tc pixel Free CRDL Stock Alerts

Cardiol Therapeutics (CRDL) Competitors

Cardiol Therapeutics logo
C$2.49 -0.18 (-6.74%)
As of 09/23/2026 04:00 PM Eastern
Compare

CRDL vs. GUD, THCX, DHT.UN, TLRY, and CMED

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Knight Therapeutics (GUD), Hydropothecary (THCX), DRI Healthcare Trust (DHT.UN), Tilray Brands (TLRY), and CanniMed Therapeutics (CMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Knight Therapeutics?

Cardiol Therapeutics (TSE:CRDL) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Knight Therapeutics has a consensus price target of C$9.50, indicating a potential downside of 5.85%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cardiol Therapeutics has a beta of 0.584931, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, indicating that its stock price is 129% less volatile than the broader market.

In the previous week, Knight Therapeutics had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.64 beat Knight Therapeutics' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cardiol Therapeutics Positive
Knight Therapeutics Neutral

Knight Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A
Knight TherapeuticsC$547.31M1.81-C$30.73MC$0.1567.27

0.1% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Knight Therapeutics has a net margin of 2.72% compared to Cardiol Therapeutics' net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -180.13% -54.15%
Knight Therapeutics 2.72%1.91%0.51%

Summary

Knight Therapeutics beats Cardiol Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Hydropothecary's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HydropothecaryN/A N/A N/A
Cardiol Therapeutics N/A -180.13%-54.15%

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HydropothecaryN/AN/AN/AN/AN/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.64 beat Hydropothecary's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Hydropothecary Neutral
Cardiol Therapeutics Positive

Summary

Cardiol Therapeutics beats Hydropothecary on 3 of the 5 factors compared between the two stocks.

How does Cardiol Therapeutics compare to DRI Healthcare Trust?

Cardiol Therapeutics (TSE:CRDL) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

0.1% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

DRI Healthcare Trust has a net margin of 5.02% compared to Cardiol Therapeutics' net margin of 0.00%. DRI Healthcare Trust's return on equity of 2.06% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -180.13% -54.15%
DRI Healthcare Trust 5.02%2.06%4.22%

Cardiol Therapeutics has a beta of 0.584931, suggesting that its share price is 42% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.365327, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, DRI Healthcare Trust had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for DRI Healthcare Trust and 0 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.64 beat DRI Healthcare Trust's score of 0.51 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cardiol Therapeutics Positive
DRI Healthcare Trust Positive

DRI Healthcare Trust has higher revenue and earnings than Cardiol Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A
DRI Healthcare TrustC$172.34M5.79C$9.73M-C$0.80N/A

DRI Healthcare Trust has a consensus price target of C$25.60, indicating a potential upside of 41.20%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts plainly believe DRI Healthcare Trust is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

Summary

DRI Healthcare Trust beats Cardiol Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Cardiol Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -15.22%. Tilray Brands' return on equity of -8.85% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-15.22% -8.85% -1.41%
Cardiol Therapeutics N/A -180.13%-54.15%

Cardiol Therapeutics has lower revenue, but higher earnings than Tilray Brands. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray BrandsC$915.45M0.89-C$183.24M-C$1.09N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A

5.6% of Tilray Brands shares are owned by institutional investors. Comparatively, 0.1% of Cardiol Therapeutics shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by company insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.64 beat Tilray Brands' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Tilray Brands Neutral
Cardiol Therapeutics Positive

Tilray Brands presently has a consensus price target of C$13.30, indicating a potential upside of 129.31%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Tilray Brands has a beta of 3.215277, indicating that its share price is 222% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.584931, indicating that its share price is 42% less volatile than the broader market.

Summary

Tilray Brands beats Cardiol Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.64 beat CanniMed Therapeutics' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
CanniMed Therapeutics Neutral
Cardiol Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CanniMed TherapeuticsN/AN/AN/AN/AN/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CanniMed Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CanniMed TherapeuticsN/A N/A N/A
Cardiol Therapeutics N/A -180.13%-54.15%

Summary

Cardiol Therapeutics beats CanniMed Therapeutics on 3 of the 5 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDL vs. The Competition

Export
MetricCardiol TherapeuticsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$324.44MC$12.60BC$7.31BC$12.84B
Dividend YieldN/A2.63%2.52%6.27%
P/E Ratio-7.32792.28274.0840.36
Price / SalesN/A862.22638.219.35
Price / Cash0.9888.6477.8082.29
Price / Book11.9110.5910.474.69
Net Income-C$42.93MC$2.81BC$3.49BC$299.09M
7 Day Performance-5.68%-0.11%-0.67%0.01%
1 Month Performance-3.49%-1.34%-3.17%-2.14%
1 Year Performance64.90%2.86%15.14%20.17%

Cardiol Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDL
Cardiol Therapeutics
N/AC$2.49
-6.7%		N/A+61.7%C$324.44MN/AN/A20
GUD
Knight Therapeutics
0.3685 of 5 stars		C$9.85
+1.2%		C$9.50
-3.6%		+67.1%C$967.59MC$547.31M65.67725
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A
DHT.UN
DRI Healthcare Trust
2.8205 of 5 stars		C$16.95
+0.1%		C$25.20
+48.7%		+27.8%C$931.62MC$172.34MN/AN/A
TLRY
Tilray Brands
1.2073 of 5 stars		C$5.56
-3.0%		C$13.30
+139.2%		-66.5%C$764.95MC$915.45MN/A2,650

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CRDL) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel